Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep;11(3):467-71.
doi: 10.1007/s10689-012-9537-3.

Causes of death of mutation carriers in Finnish Lynch syndrome families

Affiliations

Causes of death of mutation carriers in Finnish Lynch syndrome families

Kirsi Pylvänäinen et al. Fam Cancer. 2012 Sep.

Abstract

Lynch syndrome (LS) is an autosomal dominant cancer syndrome including increased life-long risk for colorectal (CRC) and endometrial (EC) cancer, but also for cancers of other types. The risk for CRC is up to 70-80 % and for EC up to 50-60 %. Due to screening and early diagnosing the mortality related to CRC and EC seems to be low. In spite of many studies on surveillance of mutation carriers, there is no comprehensive evaluation on causes of death in LS families. The disease history and cause of death of all the deceased, tested mutation carriers and their mutation negative relatives in the Finnish LS families (N = 179) was examined utilizing hospital records and relevant national registries. Out of 1069 mutation carriers 151 had succumbed; 97 (64 %) from cancer. Out of 1146 mutation-negative family 44 members had died; 11 (25 %) of them from cancer. In 12 (7.7 %) of the deceased mutation carriers no cancer had been diagnosed. The mean age of death from cancer was 63.2 years vs. 68.8 years from non-cancer causes. Only 7.9 % of the patients with CRC had died from CRC and 5 % of those with EC, respectively. 61 % of the cancer deaths were related to extra-colonic, extra-endometrial cancers. The cumulative overall and cancer specific death rates were significantly increased in Mut+ compared to Mut- family members. Even surveillance yields decrease in the life-long risk and mortality of the most common cancers CRC and EC in LS, almost all mutation carriers will contract with cancer, and two thirds of the deceased have died from cancer. This should be taken in account in genetic counseling. Mutation carriers should be encouraged to seek help for abnormal symptoms.

PubMed Disclaimer

Similar articles

  • The contribution of Lynch syndrome to early onset malignancy in Ireland.
    Talbot A, O'Donovan E, Berkley E, Nolan C, Clarke R, Gallagher D. Talbot A, et al. BMC Cancer. 2021 May 26;21(1):617. doi: 10.1186/s12885-021-08263-z. BMC Cancer. 2021. PMID: 34039291 Free PMC article.
  • Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members.
    Järvinen HJ, Renkonen-Sinisalo L, Aktán-Collán K, Peltomäki P, Aaltonen LA, Mecklin JP. Järvinen HJ, et al. J Clin Oncol. 2009 Oct 1;27(28):4793-7. doi: 10.1200/JCO.2009.23.7784. Epub 2009 Aug 31. J Clin Oncol. 2009. PMID: 19720893
  • Risks of Lynch syndrome cancers for MSH6 mutation carriers.
    Baglietto L, Lindor NM, Dowty JG, White DM, Wagner A, Gomez Garcia EB, Vriends AH; Dutch Lynch Syndrome Study Group; Cartwright NR, Barnetson RA, Farrington SM, Tenesa A, Hampel H, Buchanan D, Arnold S, Young J, Walsh MD, Jass J, Macrae F, Antill Y, Winship IM, Giles GG, Goldblatt J, Parry S, Suthers G, Leggett B, Butz M, Aronson M, Poynter JN, Baron JA, Le Marchand L, Haile R, Gallinger S, Hopper JL, Potter J, de la Chapelle A, Vasen HF, Dunlop MG, Thibodeau SN, Jenkins MA. Baglietto L, et al. J Natl Cancer Inst. 2010 Feb 3;102(3):193-201. doi: 10.1093/jnci/djp473. Epub 2009 Dec 22. J Natl Cancer Inst. 2010. PMID: 20028993 Free PMC article.
  • Colorectal surveillance in Lynch syndrome families.
    de Vos tot Nederveen Cappel WH, Järvinen HJ, Lynch PM, Engel C, Mecklin JP, Vasen HF. de Vos tot Nederveen Cappel WH, et al. Fam Cancer. 2013 Jun;12(2):261-5. doi: 10.1007/s10689-013-9631-1. Fam Cancer. 2013. PMID: 23525799 Review.
  • Prophylactic surgery in Lynch syndrome.
    Celentano V, Luglio G, Antonelli G, Tarquini R, Bucci L. Celentano V, et al. Tech Coloproctol. 2011 Jun;15(2):129-34. doi: 10.1007/s10151-010-0666-0. Epub 2011 Feb 2. Tech Coloproctol. 2011. PMID: 21287222 Review.

Cited by

References

    1. Clin Cancer Res. 2009 Sep 15;15(18):5772-83 - PubMed
    1. Gastroenterology. 2010 Jun;138(7):2300-6 - PubMed
    1. J Clin Oncol. 2009 Oct 1;27(28):4793-7 - PubMed
    1. Fam Cancer. 2006;5(2):175-8 - PubMed
    1. Gut. 2011 Jul;60(7):950-7 - PubMed

Publication types

MeSH terms

LinkOut - more resources